C71
Conditions
Interventions
Group 1: Patients =70 years old, Karnfosky Performance Status =60% with newly diagnosed glioblastoma or gliosarcoma are additionally treated with Optune® before and during the standard therapy (radiot
Sponsors
Universitätsklinikum Essen
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: •Pathological evidence of glioblastoma or gliosarcoma using latest WHO classification criteria •Negative IDH status on immunohistochemistry or sequencing •Patient received brain tumor resection or biopsy and further treatment regime foresees radiotherapy with or without concomitant chemotherapy •General indication for whole treatment regimen was a common deci-sion of a multidisciplinary team within brain tumor board and in accordance with the national and/or international guidelines for the treatment of glioblastoma patients •KPS = 60% (Study arm A), KPS = 50% (Study arm B) •Life expectancy at least 3 months •Participants of child-bearing age must use effective contraception •Treatment with TTFields may start 2-4 weeks post resection and 1-2 weeks prior to radiotherapy •Subjects with the ability to follow study instructions and likely to attend and complete all required visits •Written informed consent of the subject
Exclusion criteria
Exclusion criteria: General Exclusion Criteria: •Subjects not able to give consent •Subject without legal capacity who is unable to understand the nature, scope, significance, and consequences of this clinical trial •Simultaneously participation in another clinical trial or participation in any clinical trial involving administration of an investigational medicinal product within 30 days prior to clinical trial beginning •Subjects with a physical or psychiatric condition which at the investigator’s discretion may put the subject at risk may confound the trial results or may interfere with the subject’s participation in this clinical trial •Known or persistent abuse of medication, drugs or alcohol Exclusion criteria regarding special restrictions for females: •Current or planned pregnancy or nursing women •Females of child-bearing potential, who are not using and not willing to use medically reliable methods of contraception for the entire study duration (such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices) unless they are surgically sterilized / hysterectomized or there are any other criteria considered sufficiently reliable by the investigator in individual cases Indication-specific exclusion criteria: •Infra-tentorial tumor •Significant comorbidities at baseline, which would prevent possible chemotherapy, including: oPlatelet count 3 times the upper limit of normal oTotal bilirubin above the normal range oSerum creatinine > 1.7 mg/dl •Patients with clinically significant liver-, renal- or blood disorder •Patients with known additional significant neurological disease (e.g. primary seizure disorder*, dementia, progressive degenerative neuro-logical disease, meningitis or encephalitis, hydrocephalus with in-creased intracranial pressure) *Patients with brain tumor-related epilepsy, seizure-free under antiepileptic therapy are eligible •Documented allergy to conductive hydrogel (e.g. ECG (electrocardio-gram) sticker or TENS (transcutaneous electrical nerve stimulation) electrodes) •Active implanted medical device (e.g. deep brain stimulators, spinal cord stimulators, vagus nerve stimulators, pacemakers, defibrillators and programmable shunts)or documented clinically significant arrhythmias •Skull defect (e.g. missing bone with no replacement) and bullet frag-ments in the skull •History of hypersensitivity reaction to temozolomide or lomustine •History of HIV infection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary end-point is safety and tolerance and will be based on the frequency of a set of predefined Theraoy Limiting Toxicities (TLT) assessed weekly during treat-ment and up to 4 weeks after the end of radiotherapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| •TLT 4 weeks after radiotherapy completion until the end of treatment or tumor recurrence, whichever occurs first (overall and considering concomitant chemotherapy) •TLT during treatment and up to 4 weeks after end of radiotherapy con-sidering concomitant chemotherapy •Progesssion free survival (PFS) •Overall survival (OS) •Radiological response (RANO criteria) •Adverse events as measured by CTCAE •Quality of life (at end of RT, 4 weeks after the end of RT, after 3, 5 and 7 months of TTFields treatment)including subscores •Estimation number of fully compliant patients •Estimation of the delivered cumulative dose distribution over the treatment series for each patient from the KV-image guidance data and comparison with the planned dose distribution. Dose deviations by more than 3.5% in more than 1 cm3 within the PTV or if more than 5% in less than 1 cm3 will be considered as relevant. •Number of patients with = grade 3 skin toxicity (CTCAE) separately in-to patients with high 1 and low radiation risk. 1: high risk group: patients who received a surface dose >70% of the prescribed dose within or up to 6 mm below the skin on a scalp area are of >50 cm2 | — |
Countries
Germany
Contacts
Public ContactMartin Glas
Abteilung Klinische NeuroonkologieKlinik für NeurologieUniversitätsklinikum Essen
Outcome results
None listed